Emmes

Activities: Drug Delivery

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  4. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
  5. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

Related Content

Research & Development

Emmes acquires vaccine clinical trials expert VaxTRIALS

The CRO Emmes has announced the acquisition of VaxTRIALS, an organisation who's staff members manage and monitor vaccine clinical trials throughout Latin America
Manufacturing

Emmes recruits new Vice President Matt Honan

Honan served most recently as senior director, M&A and business development, at Quest Diagnostics
Manufacturing

Emmes appoints Ching Tian as Chief Innovation Officer

“I’m very proud to have contributed to the industry’s Decentralised Clinical Trials (DCT) and digital evolution over the past five years"
Manufacturing

Emmes creates cell and gene therapy research

The centre will combine a team of 100 researchers to capitalise on the company’s 35 years of cell and gene therapy experience
Research & Development

Emmes rapidly expands CRO operations in India

Global CRO’s India office reports surging growth from Western, regional and local trial customers. Driven by deep vaccines and infectious diseases expertise and enhanced study startup capabilities
Drug Delivery

Emmes acquires Clinical Edge

The combination of Optym, Emmes' ophthalmology certification unit, and Clinical Edge will make the organisation a leader in ophthalmic certification and training services
Subscribe now